Patients with prostate cancer have a new hope, a treatment that reduces the risk of death by 50 percent. While the method of the treatment, (also known as NADT), androgen deprivation therapy is not new, the changes in the form that can be used are significant.
NADT is usually given to patients in stages of prostate cancer, but new research suggests that with only six months of treatment could cure in many cases. It works by reducing levels of male hormones that cause prostate cancer. data, published in the journal The Lancet Oncology, also show that the treatment may work for a maximum of 10 years, and comes with few side effects.
“This is an important test and has two clear messages for current clinical practice,” wrote Chris Parker, of the Royal Marsden hospital in West London cancer, in an article that accompanies the research.
“First, confirms that NADT significantly reduces mortality after radiation therapy for high-risk prostate cancer, and is a standard of care.” “Secondly, helps to resolve uncertainty about the NADT duration, and suggests that men who received NADT must have at least six months of treatment” the Express reported.
The results positive for prostate cancer have come to leaps and bounds in recent years with increasing thanks to early detection and improved treatment survival rates. However, more than 250,000 men have prostate cancer and almost 40,000 more are diagnosed each year.
Initially it was believed that a long-term hormone therapy would risk of serious side effects, but maintaining the duration of treatment of six months seem to have annulled the risks according to the research conducted by the Australian team.
By comparing the results of males treated with radiotherapy alone, and those receiving radiotherapy and NADT, the study showed that only 11 percent died within a decade when given both treatments, compared with 22 percent in the first instance. 
